TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸ABEO

Abeona Therapeutics Inc. - Common Stock

NASDAQ
$2.45
▼ $2.16 (-46.8%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 20 Nov 2026
H $7.65L $2.09-55.5%
$7.65$6.54$5.43$4.31$3.2$2.09$2.44
RSI (14)
Intraday · 15-minSell-15RSI 40DowntrendMACD Bullishfor day-trading context — not advice

Technical signal

Strong sell-45
RSI (14)27
oversold 30overbought 70
Trend
Downtrend
MACD
Bearish
Bollinger
Within bands
vs 20-day
below
vs 50-day
below
vs 200-day
below
Support
$2.09
Resistance
$4.73
  • Price is below its 50-day average (medium-term weakness).
  • RSI is 27 — oversold, a level some traders read as a potential entry zone.

Signal backtest · 2026-02-19 → 2026-11-20

Strategy return
+6.7%
Buy & hold
-53.8%
Trades
6
Win rate
67%

$100,000.00 invested would be worth $106,689.75 (+6.7%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Abeona Therapeutics Inc.· Biotechnology

source: yahoo

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Sector
Healthcare
Industry
Biotechnology
Employees
226
Headquarters
Cleveland, United States
www.abeonatherapeutics.com ↗

Fundamentals

No fundamental data is currently available for this listing from our data providers.

Recent news

News sentiment:— Neutral2↑ · 2↓ · 4–
  • Abeona Therapeutics (ABEO) Stock Sees Fair Value Falls As Zevaskyn Ramp Concerns Grow▼ Negative
    Simply Wall St. · 14 Nov 2026
  • ABEO: In-Licenses Phase 3 Candidate for Eosinophilic Esophagitis— Neutral
    Zacks Small Cap Research · 13 Nov 2026
  • Abeona Therapeutics Plans New Phase 3 Trial for ABO-801 as ZEVASKYN Launch Expands▲ Positive
    MarketBeat · 12 Nov 2026
  • AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

▼ Negative
BioPharma Dive · 11 Nov 2026
  • Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences— Neutral
    GlobeNewswire · 10 Nov 2026
  • Abeona Therapeutics Inc (ABEO) (Q3 2026) Earnings Call Highlights: ZivaSkin Revenue Jumps 18% ...▲ Positive
    GuruFocus.com · 09 Nov 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.